Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct 17;17(10):1725.
doi: 10.3390/ijms17101725.

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives

Emanuele D'Amico  1 , Francesco Patti  2 , Aurora Zanghì  3 , Mario Zappia  4
Affiliations
Review

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives

Emanuele D'Amico et al. Int J Mol Sci. .

Abstract

Using the term of progressive multiple sclerosis (PMS), we considered a combined population of persons with secondary progressive MS (SPMS) and primary progressive MS (PPMS). These forms of MS cannot be challenged with efficacy by the licensed therapy. In the last years, several measures of risk estimation were developed for predicting clinical course in MS, but none is specific for the PMS forms. Personalized medicine is a therapeutic approach, based on identifying what might be the best therapy for an individual patient, taking into account the risk profile. We need to achieve more accurate estimates of useful predictors in PMS, including unconventional and qualitative markers which are not yet currently available or practicable routine diagnostics. The evaluation of an individual patient is based on the profile of disease activity.Within the neurology field, PMS is one of the fastest-moving going into the future.

Keywords: future perspectives; personalized treatment; progressive multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

Francesco Patti has served on the scientific advisory board for Teva, Biogen-Idec, Bayer-Schering, Novartis, and has received honoraria as a speaker for Teva, Biogen, Merck-Serono, Bayer-Schering, Genzyme/Sanofi, and Novartis. Emanuele D’Amico received travel funding by Teva, Biogen, Merck-Serono, Bayer-Schering, Genzyme/Sanofi, Novartis. Aurora Zanghì has nothing to disclose. Mario Zappiahas served on scientific advisory boards and received honoraria from UCB-Union ChimiqueBelge and Lundbeck, and has received scientific grants from the Italian Medicines Agency (AIFA) and Novartis.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lugaresi A., di Ioia M., Travaglini D., Pietrolongo E., Pucci E., Onofrj M. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr. Dis. Treat. 2013;9:893–914. doi: 10.2147/NDT.S45144. - DOI - PMC - PubMed
    1. Lublin F.D., Reingold S.C., Cohen J.A., Cutter G.R., Sørensen P.S. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83:278–286. doi: 10.1212/WNL.0000000000000560. - DOI - PMC - PubMed
    1. Miller D.H., Leary S.M. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6:903–912. doi: 10.1016/S1474-4422(07)70243-0. - DOI - PubMed
    1. Afsaneh S., Darin T., Okuda O.S. Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics. 2016;13:58–69. - PMC - PubMed
    1. Ontaneda D., Fox R.J., Chataway J. Clinical trials in progressive multiple sclerosis: Lessons learned and future perspectives. Lancet Neurol. 2015;14:208–223. doi: 10.1016/S1474-4422(14)70264-9. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources